Lead Sponsor

Huashan Hospital

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

•fluctuating muscle weakness and fatigability classified as the Myasthenia Gravis Foundation of America (MGFA) clinical classification Type IIa-IVa;
•more than 10% amplitude decrement in low frequency repetitive nerve stimulation, and less than 10% amplitude increment in high frequency repetitive nerve stimulation;
•understanding and assigning the informed consent form, and having a good compliance with treatment.
•meet all of the criteria in above as well as at least one of the below:
•refractory: insufficient response to full dose- and course- steroids treatment (0.75-1mg per kg per day for at least 3-6 months), failure to respond adequately to tacrolimus (no less than 3mg per day) for 3 months;
•severe or intolerable adverse effects from conventional immunosuppressive therapy.

•positive for muscle-specific kinase (MuSK) antibodies;
•a tumor history except for thymoma;
•a history of Type B and Type C hepatitis;
•a history of tuberculosis or T-SPOT.TB tset positivity;
•hepatic, renal and cardial insufficiency (baseline: ALT/AST\>50U/L;BNP\>200pg/ml）;
•severe allergy or infection, or chronic or recurrent infection;
•pregnancy;
•hyperlipidemia;
•participating other clinical trials

Related studies

NCT04806620 · Post-Acute COVID-19 Syndrome, ME/CFS, and more

NCT06455709 · Myasthenia Gravis, Generalized

NCT06958939 · Myasthenia Gravis, Generalized

NCT06485232 · Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, and more

NCT03759366 · Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, and more

Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study